Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Levofloxacin inhalation - Horizon Pharma

Drug Profile

Levofloxacin inhalation - Horizon Pharma

Alternative Names: Aeroquin; Inhaled levofloxacin hemihydrate - Horizon Pharma; MP 376; Quinsair

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mpex Pharmaceuticals
  • Developer Adare Pharmaceuticals; Horizon Pharma
  • Class Antibacterials; Fluoroquinolones; Small molecules
  • Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis-associated respiratory tract infections
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cystic fibrosis-associated respiratory tract infections
  • Preclinical Bronchiectasis; Mycobacterial infections
  • Discontinued Respiratory tract infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Cystic-fibrosis-associated-respiratory-tract-infections(In children) in USA (Inhalation, Aerosol)
  • 24 May 2017 Levofloxacin inhalation solution (QUINSAIR™) licensed to Chiesi Farmaceutici SpA in Europe, the Middle East and Africa (EMEA) regions
  • 22 Dec 2016 Launched for Cystic fibrosis-associated respiratory tract infections in Canada (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top